PROVECTUS BIOPHARMACEUTICALS, INC. 8-K

What Happened

• Provectus Biopharmaceuticals, Inc. filed a Form 8-K (Item 7.01) reporting Regulation FD disclosure tied to its annual meeting of stockholders held on June 18, 2026.
• The company provided an update covering clinical development, regulatory affairs, drug discovery, manufacturing, intellectual property, business development, and corporate development.
• The presentation slides used at the 2026 Annual Meeting are attached to the filing as Exhibit 99.1 and are incorporated by reference.

Key Details

• Date of event: June 18, 2026 (annual meeting of stockholders).
• Filing: Current Report on Form 8-K under Item 7.01 (Regulation FD disclosure).
• Exhibit: 99.1 — "2026 Annual Meeting of Stockholders" presentation slides included with the 8‑K.
• Topics disclosed: clinical programs, regulatory status, R&D/drug discovery, manufacturing, IP, business and corporate development.

Why It Matters

• The updates cover material areas (clinical and regulatory progress, IP, manufacturing) that can influence the value and near-term catalysts for a biotech company’s pipeline — information investors monitor for clinical readouts and regulatory milestones.
• Because this was filed under Regulation FD, the information was made public and broadly available to all investors (reducing selective disclosure risk).
• The filing does not report financial results or executive changes; investors should review the attached presentation (Exhibit 99.1) for specific program timelines, data points, or milestones referenced.